



**24-Hour Helpline for Access to Expert Management Advice
for Food Allergy-Related Anaphylaxis in Children: Protocol
for a Pragmatic Randomised Controlled Trial**

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2012-001282 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 09-Apr-2012 |
| Complete List of Authors: | Kelleher, Maeve Hourihane, Jonathan DunnGalvin, Audrey Cullinane, Claire Fitzsimons, John Sheikh, Aziz; University of Edinburgh, Division of Community Health Sciences |
| Primary Subject Heading: | Immunology (including allergy) |
| Secondary Subject Heading: | Emergency medicine |
| Keywords: | ACCIDENT & EMERGENCY MEDICINE, IMMUNOLOGY, Paediatric A&E and ambulatory care < PAEDIATRICS |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **24-Hour Helpline for Access to Expert Management Advice for Food Allergy-**
4 **Related Anaphylaxis in Children: Protocol for a Pragmatic Randomised**
5 **Controlled Trial**
6
7
8
9

10 Maeve Kelleher MB MRCP¹

11 Jonathan O'B Hourihane DM, FRCPI¹

12 Audrey DunnGalvin PhD¹

13 Claire Cullinane BSc¹

14 John Fitzsimons FRCPI²

15 Aziz Sheikh FRCGP, FRCP³
16
17
18
19
20
21
22
23
24

25 1 Paediatrics and Child Health, University College Cork, Ireland

26 2 Paediatrics, Our Lady of Lourdes Hospital, Drogheda, Co Louth, Ireland

27 3 Allergy & Respiratory Research Group, Centre for Population Health Sciences, The University of
28 Edinburgh, Scotland
29
30
31
32
33

34 Correspondence to: Professor Aziz Sheikh, Professor of Primary Care Research & Development,
35 Centre for Population Health Sciences, The University of Edinburgh, Medical School, Doorway 3,
36 Teviot Place, Edinburgh EH8 9AG, Scotland. Tel: +44 (0)131 651 4151; Fax: +44 (0)131 650 9119;
37 Email: aziz.sheikh@ed.ac.uk
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

INTRODUCTION: Anaphylaxis is an important, potentially life-threatening paediatric emergency. It is responsible for considerable morbidity and, in some cases, death. Poor outcomes may be associated with an inability to differentiate between milder and potentially more severe reactions and an associated reluctance to administer self-injectable adrenaline. This study aims to assess the effectiveness of 24-hour telephone access to specialist paediatric allergy expert advice in improving the quality of life of children and their families with potentially life-threatening food allergy (i.e. anaphylaxis) compared with usual clinical care.

METHODS AND ANALYSIS: Children aged less than 16 years with food allergy and who carry an adrenaline auto-injector will be recruited from the Paediatric Allergy Clinic at Cork Hospital, Ireland and baseline disease specific quality of life will be ascertained using the validated Food Allergy Quality of Life Questionnaire (FAQLQ). Participants will be randomised for a period of six months to the 24-hour telephone specialist support line or usual care. The primary outcome measure of interest is a change in FAQLQ scores, which will be assessed at 1 and 6 months post-randomisation. Analysis will be on an intention-to-treat basis using a 2x3 repeated measures within-between ANOVA. Although lacking power, we will in addition assess the impact of the intervention on a range of relevant process and clinical endpoints.

ETHICS AND DISSEMINATION: This trial protocol has been approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals. The findings will be presented at international scientific conferences and will be reported on in the peer-reviewed literature in early 2013.

TRIAL REGISTRATION: Current Controlled Trials: ISRCTN29793562

INTRODUCTION

Anaphylaxis is an important, potentially life-threatening paediatric emergency. Food is responsible for the majority of anaphylaxis cases in the paediatric population.⁽¹⁾ Egg, milk, peanuts and tree nuts are the most common food allergens in the preschool population; peanut and tree nuts are the most common allergen triggers in older children. There is a wide spectrum of allergic reactions to these allergens ranging from minor urticarial reactions to anaphylaxis, with the associated risk of fatality.

Anaphylaxis is managed via a two-pronged approach: firstly lifestyle modification to avoid the allergen; and secondly the acute management of the anaphylactic event itself.^(2,3,4) Those children who have had anaphylaxis, or who are judged to be at high risk of anaphylaxis, are prescribed adrenaline (epinephrine) auto-injectors.⁽⁵⁾ These are to be carried on their person, or by their carers, at all times in case of accidental exposure to the allergen(s) in question. This is important as most accidental exposures and subsequent reactions tend to occur in community settings⁽¹⁾ and because of the typically rapid onset and progression of reactions, most young people and their families do not have immediate access to medical support when this is most required.

Despite being prescribed an adrenaline auto-injector and being shown the correct method of administration, many young people and/or parents still often report being unsure when to administer this treatment.^(6,7) They often worry whether the reaction is severe enough to warrant an injection of adrenaline or whether their child may come to harm if given unnecessary treatment.⁽⁸⁾

There is evidence that there is often a delay in administering the prescribed medication in an emergency.⁽¹⁾ This delay in administering adrenaline may lead to increased morbidity and also increases the risk of fatality. Allergy services therefore often encourage children and families/carers to use their auto-injectors if there is any doubt regarding the severity of the allergic reaction. Given the risk of further reactions and the above-described concerns about when to administer emergency treatment, it is perhaps unsurprising that studies have found that food allergy can have a

1
2
3 detrimental impact both on the children themselves and also on family quality of life.^(9,10) There is
4
5 however as yet no clear evidence on how to improve clinical and/or psychological outcomes in this
6
7 population.
8
9

10 In the light of the above factors, we hypothesise that: firstly, uncertainty about the likely severity of
11
12 their child's reaction (ranging from no reaction to mild to life-threatening) on accidental re-exposure
13
14 to the allergenic food in question; and secondly, what a patient or carer must do if a reaction occurs,
15
16 both contribute significantly to parental/child anxiety. We further hypothesise that this uncertainty
17
18 could be ameliorated by real-time expert clinical guidance and support.
19
20

21 We propose therefore to test the effectiveness of giving parents and carers of children and
22
23 teenagers with known food allergy, who are medically considered to be at sufficient risk of
24
25 anaphylaxis that they have been prescribed and trained in the use of adrenaline auto-injectors, 24-
26
27 hour telephone access (intervention arm) or office hour access (routine care arm) to expert advice
28
29 from the clinical allergy service. We will advise parents/ carers/ teen patients randomised to the
30
31 intervention arm to ring this clinician-staffed advice line if they or their child has an allergic reaction
32
33 and they are unsure as to how to manage it. We postulate that the availability of this service will
34
35 improve disease-specific quality of life compared with families randomised to the routine care arm
36
37 who do not have this 24-hour access. We also suspect that the allergic reactions that parents or
38
39 families contact the allergy team about will be better managed as a result of the advice given. There
40
41 is currently no service such as this available in Ireland or indeed worldwide. This is, as far as we are
42
43 aware, the first ever randomised clinical trial of patient care in the field of anaphylaxis.⁽¹¹⁾
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AIMS AND OBJECTIVES

Aims

We seek to assess the effectiveness of 24-hour telephone access to specialist paediatric allergy expert advice in improving the quality of life of children and their families with potentially life-threatening food allergy (i.e. anaphylaxis) compared with usual clinical care.

Main objective

1. To compare the difference in food allergy related quality of life between the 24-hour telephone access and usual care at one- and six-months post-randomisation.

Secondary objectives

2. To compare the number and clinical severity of incidents of suspected/confirmed allergic reaction in both groups
3. To compare clinical and health service use outcomes in both groups.

METHODS AND ANALYSIS

Design

We will undertake a pragmatic two-arm parallel group randomised controlled trial.

Recruitment and consent

All families with food allergic children seen in the paediatric allergy outpatient clinics at Cork University Hospital will be informed about the study and invited to participate. A baseline validated

1
2
3 Food Allergy-specific Quality of Life questionnaire (FAQL) will be completed by interested family
4
5 members in relation to each child recruited.^(12,13,14) This FAQL questionnaire will be sent by post to each
6
7 family, with a stamp-addressed envelope.
8
9

10 Recruitment of families of children with food allergy who carry an adrenaline auto-injector will occur
11
12 in the paediatric allergy out-patient clinics of Cork University Hospital, which is the main centre for
13
14 specialist paediatric allergy service provision across Ireland. Notices with information about the
15
16 study will be placed around the out-patient waiting rooms. A phone number with a 24-hour
17
18 answering service will be advertised for families wishing to obtain further information about the
19
20 trial. Potentially suitable patients will also be identified from the weekly clinic preview team
21
22 meetings.
23
24

25
26 All potentially interested parents will be given further information about the study, and any
27
28 questions they may have will be answered. Children will, where appropriate on the basis of their age
29
30 and understanding, also be involved in this discussion. Written informed consent will be obtained
31
32 from all parents/guardians wishing to take part in the trial. Those over the age of eight years will also
33
34 be asked to sign an assent form in the presence of their parents.
35
36
37
38
39
40

41 ***Eligibility***

42
43 Families of children satisfying the inclusion and exclusion criteria detailed below will be eligible to
44
45 participate in the trial.
46
47

48 Inclusion criteria

- 49
50
51
52 1. <16 years of age
53
54 2. Food allergy
55
56 3. Previously prescribed an adrenaline auto-injector
57
58
59
60

- 1
- 2
- 3 4. Carers and, where appropriate, children trained by the clinical service how to use the
- 4
- 5 prescribed adrenaline auto-injector
- 6
- 7 5. First eligible food allergic child in a family with more than one eligible child.
- 8
- 9

10 Exclusion criteria

- 11
- 12
- 13 1. Awaiting food challenge and likely to undergo this challenge during the trial period
- 14
- 15 2. Experiencing another major life stressor during timeline of trial e.g. changing school
- 16
- 17 3. Second or subsequent eligible child in families with more than one already recruited child.
- 18
- 19

20 **Baseline assessment**

21 All study participants will, as noted above, fill out FAQL questionnaires prior to randomisation.

22 Parents will complete the FAQL Parent Form (FAQL-PF) as a proxy for their young children in those

23 less than 13 years. Children age 8-13 years will complete their own validated FAQL Child Form

24 (FAQL-CF) and teenagers will fill in the FAQL Teen form (FAQL-TF).

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39 **Randomisation**

40 Randomisation will be undertaken only once all participants have been recruited, thereby

41 minimising the risk of any selection biases. When all baseline questionnaires are collected the family

42 will then be independently, centrally randomised 1:1 into the intervention (I) or usual (U) care arms.

43

44 Randomisation will be on the basis of the subjects day of their date of birth being odd or even

45 numbered.⁽¹⁵⁾ The designation of odd/even date of birth to (I) or (U) arms will be determined by a

46 coin toss by an individual who is not involved in the trial. All recruited families will thus

47 simultaneously be allocated to the (I) or (U) arms, this marking the onset of the trial period.

48

49

50

51

52

53

54

55

56

57

58

59

60

Intervention and control

The (I) group will be given a direct access mobile phone number to ring in the event of a suspected serious allergic reaction. This will be given on a credit-card sized document for ease of access in the event of an emergency. The manning of this emergency 24-hour helpline will be shared between experienced members of the paediatric allergy team. In the event of a suspected serious allergic reaction, the patient or his/her parent or carer will be able to ring the on-call trial clinician for advice. Trial staff will have a standard incident report form (Appendix) to be filled out at the earliest possible time after the phone-call consultation. Their advice will be tailored according to clinical need, but will include instructions that there is either: i. No need for emergency treatment; ii. Give antihistamines by mouth and observe; or iii. Use the adrenaline auto-injector and call an ambulance. The responding staff member will keep a record of all such encounters and the advice given.

Those allocated to the U care (control) arm will receive standard care, with the option of contacting one or more of the following: the Cork University Hospital Paediatric Allergy team during working hours (Monday–Friday 8am–5pm), emergency/ambulance services, their own registered general practitioner (GP), out-of-hours primary care providers or their nearest hospital Emergency Departments .

The duration of trial period will be six months from the point of randomisation.

Outcome measures

Primary

All study participants will complete the age-appropriate (discussed above) validated FAQL at one- and six-months post randomisation; specifically, any change from baseline between intervention and control groups at the one- and six-month assessment points.

Secondary

Participants in both groups will also be asked to record any possible allergic reactions that may have occurred, which were self-managed and/or required medical advice or attention other than provided through the trial helpline. We will record the clinical details of every reported event to include: incidence, severity, administration of adrenaline, hospital attendance and death.

Statistical considerations

Analysis

We will assess the statistical significance and relative magnitude of changes over three time-points i.e. at baseline (T0), one month (T1) and six-months (T2) post-randomisation, on the FAQL scores for both the (I) and (U) care groups using a repeated measures 2x3 multivariate design.⁽¹⁶⁾ That is, the same case in either experimental or control group (group factor), will complete the questionnaires at three time-points (time factor). The effect of the factors 'time' and 'group' on the total score, and the interaction of these two factors, will be analysed using a two-way within-between groups ANOVA. The interaction will address the question; 'Are the time profiles in terms of FAQL total scores of the two groups (experimental/control) significantly different'? If improvement over time is determined, a paired sample t-test will be used to ascertain at which time-point(s) the difference can be detected. Secondary outcomes will be included in univariate and multivariate models as independent and dependent variables and controls.

Independent t-tests will be used to determine if there are differences in magnitude of improvement in FAQL scores for (I) vs. (U) groups.

1
2
3 We will calculate the responsiveness index (mean change score/SD of change score), using Cohen's
4 change index benchmarks; 0.2–0.4 (small); 0.5–0.7 (moderate); and 0.81 (large).
5
6
7

8 We will assess the reliability of the change score by computing the intra-class coefficients of change
9 in the FAQLQ. The minimal important difference (MID) will also be calculated. Because the validity
10 of a retrospective assessment of change has been questioned, we will determine the MID by
11 computing the standard error of measurement (SEM ($sp(1-r)$)), using baseline FAQLQ scores as an
12 'anchor'.
13
14
15
16
17
18
19

20 The Last Observation Carried Forward (LOCF) imputation method will be used to deal with missing
21 data, since this is an appropriate method for longitudinal studies (i.e. repeated measures have been
22 taken per subject by time point).⁽¹⁸⁾
23
24
25
26
27

28 Analysis will be on an intention-to-treat basis by the trial statistician who will be blinded to
29 allocation. There are no interim analyses planned.
30
31
32

33 Power

34 We will utilise a within/between repeated measures analysis of variance. An a priori total sample
35 size required x power ($1-\beta$ err prob), for a repeated measures within-between ANOVA analysis is 16
36 in each age group to yield a statistically significant result at >90% power with a 0.5 effect level.⁽¹⁷⁾
37
38
39
40
41
42

43 'Within' refers to expected differences between three time periods (T0, T1 and T2) and 'between'
44 refers to expected differences between the intervention and control groups.
45
46
47
48
49

50 **F tests** - ANOVA: Repeated measures, within-between interaction


51 **Analysis:** A priori: Compute required sample size

52 **Input:** Effect size f = 0.5

53 α err prob = 0.05
54
55
56
57
58
59
60

| | | |
|--|---|-----------|
| Power (1- β err prob) | = | 0.95 |
| Number of groups | = | 2 |
| Repetitions | = | 3 |
| Corr among rep measures | = | 0.4 |
| Nonsphericity correction ϵ | = | 1 |
| Output: Noncentrality parameter λ | = | 20.000000 |
| Critical F | = | 3.340386 |
| Numerator df | = | 2.000000 |
| Denominator df | = | 28.000000 |
| Total sample size | = | 16 |
| Actual power | = | 0.973792 |

Figure 1: A – priori total sample size required x power (1- β err prob), for a repeated measures within-between ANOVA analysis



With an anticipated drop-out rate of 20%, we therefore plan to recruit a total of 50 families.

ETHICS AND DISSEMINATION

Ethical approval has been obtained by the Clinical Research Ethics Committee of the Cork Teaching Hospitals (30.05.2011). All patients are aware that their participation is voluntary and they may withdraw from study at any time.

The PI for the trial is Jonathan Hourihane and he will lead the Trial Management Group and he is responsible for the overall governance and running of this trial. Other members of the Trial Management Group are: Maeve Kelleher, John Fitzsimons, Audrey DunnGalvin, Claire Cullinane and Aziz Sheikh, and they will support the PI in delivering this trial. Audrey DunnGalvin is the trial statistician.

We plan to report our findings at major national and international scientific conferences. We also plan to publish our findings in the peer-reviewed literature. We anticipate being in a position to report on findings in early 2013.

ACKNOWLEDGEMENTS: We are very grateful to the children and their families who have agreed to participate in this trial.

CONFLICT OF INTERESTS: None known.

AUTHORS' CONTRIBUTIONS: JOH and AS conceived the idea for this trial, and this was then further developed in association with MH and ADG. MH led the drafting of this manuscript, which was critically commented on by all co-authors.

FUNDING STATEMENT: 'This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

REFERENCES

1. De Silva SL, Mehr S, Tey D, Tang MLK. Paediatric anaphylaxis: a 5 year retrospective review. *Allergy* 2008; 63: 1071–107.
2. Walker S, Sheikh A. Managing anaphylaxis: effective emergency and long-term care are necessary. *Clin Exp Allergy* 2003; 33: 1015-18.
3. Soar J, Pumphrey R, Cant A, Clarke S, Corbett A, Dawson P et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Working Group of the Resuscitation Council (UK). *Resuscitation* 2008; 77: 157-69
4. Simons FE, Arduso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J et al. World Allergy Organization anaphylaxis guidelines: Summary. *J Allergy Clin Immunol* 2011; 127: 587-93.e1-22.
5. Muraro A, Roberts G, Clark A et al The management of anaphylaxis in childhood: position paper of the EAACI. *Allergy* 2007; 62: 857–71.
6. Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen). *J Allergy Clin Immunol* 2000; 106: 171-76.
7. Arkwright P, Farragher AJ. Factors determining the ability of parents to effectively administer intramuscular adrenaline to food allergic children. *Pediatr Allergy Immunol* 2006; 17: 227–29.
8. Kim S, Sincacore J, Pongracic J. Parental use of EpiPen for children with food allergies. *J Allergy Clin Immunol* 2005; 116: 164-68.
9. Sicherer S, Noone S, Munoz-Furlong. The impact of childhood food allergy on quality of life. *Ann Asthma, Allergy Immunol* 2001; 87: 461-464.
10. Avery N, King RM, Knight S, Hourihane JO'B. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol* 2003; 14: 378–82.
11. Simons FE, Sheikh A. Evidence-based management of anaphylaxis. *Allergy* 2007; 62: 827-29.
12. DunnGalvin A, de BlokFlokstra BM, Burks AW, Dubois AE, Hourihane JO. Food allergy QoL questionnaire for children aged 0-12 years: content, construct, and cross-cultural validity. *Clin Exp Allergy* 2008; 38: 977-86.
13. Flokstra-de Blok BM, DunnGalvin A, Vlieg-Boerstra BJ, Oude Elberink JN, Duiverman EJ, Hourihane JO, et al. Development and validation of the self-administered Food Allergy Quality of Life Questionnaire for Adolescents. *J Allergy Clin Immunol* 2008; 122: 139-144.e2

14. de BlokFlokstra, DunnGalvin A, Vlieg-Boerstra BJ, Oude Elberink JN, Duiverman EJ, Hourihane JO, et al. Development and validation of a self-administered Food Allergy Quality of Life Questionnaire for children. *Clin Exp Allergy* 2009; 39: 127–37.
15. Routsis C, Gerovasili V, Vasileiadis I, Karatzanos E, Pitsolis T, Tripodaki E et al. Electrical muscle stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. *Crit Care* 2010; 14: R74.
16. Hinkelmann, Klaus & Kempthorne, Oscar. *Design and Analysis of Experiments*. 2008;I and II (Second ed.). Wiley.
17. Cohen J. A power primer. *Psychol Bull* 1992; 112: 155–59.
18. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. *Am J Psychiatry* 2009; 166: 639-41.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix

Incident Report Form

Patient Name _____

Staff member Name _____

Caller Mother/father/ patient/ other _____

(Please specify)

Time of call (24h) __ : __ h

Patient location _____

Food suspected _____

How much eaten? _____

Time since ingestion _____

Asthma y/n _____

Current condition

Advice to be given

Rash only Give antihistamine, Do not Use Anapen yet

Rash and swelling Give antihistamine, Do Not Use Anapen yet

Cough/hoarseness Use Anapen, call ambulance, go to hospital

Wheeze Use Anapen, call ambulance, go to hospital

Dizzy/collapse Use Anapen, call ambulance, go to hospital

Outcome (to be completed by study team in Cork, ASAP next working day)



**24-Hour Helpline for Access to Expert Management Advice
for Food Allergy-Related Anaphylaxis in Children: Protocol
for a Pragmatic Randomised Controlled Trial**

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2012-001282.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 05-Jul-2012 |
| Complete List of Authors: | Kelleher, Maeve Hourihane, Jonathan DunnGalvin, Audrey Cullinane, Claire Fitzsimons, John Sheikh, Aziz; University of Edinburgh, Division of Community Health Sciences |
| Primary Subject Heading: | Immunology (including allergy) |
| Secondary Subject Heading: | Emergency medicine |
| Keywords: | ACCIDENT & EMERGENCY MEDICINE, IMMUNOLOGY, Paediatric A&E and ambulatory care < PAEDIATRICS |
| | |

SCHOLARONE™
Manuscripts

only

1
2
3 1 **24-Hour Helpline for Access to Expert Management Advice for Food Allergy-**
4 **Related Anaphylaxis in Children: Protocol for a Pragmatic Randomised**
5 **Controlled Trial**
6
7
8
9

10 4
11 5 Maeve Kelleher MB MRCP¹

12 6 Jonathan O'B Hourihane DM, FRCPI¹

13 7 Audrey DunnGalvin PhD¹

14 8 Claire Cullinane BSc¹

15 9 John Fitzsimons FRCPI²

16 10 Aziz Sheikh FRCGP, FRCP³

17 11
18 12 1 Paediatrics and Child Health, University College Cork, Ireland

19 13 2 Paediatrics, Our Lady of Lourdes Hospital, Drogheda, Co Louth, Ireland

20 14 3 Allergy & Respiratory Research Group, Centre for Population Health Sciences, The University of
21 15 Edinburgh, Scotland

22 16
23
24
25 17 Correspondence to: Professor Aziz Sheikh, Professor of Primary Care Research & Development,
26 18 Centre for Population Health Sciences, The University of Edinburgh, Medical School, Doorway 3,
27 19 Teviot Place, Edinburgh EH8 9AG, Scotland. Tel: +44 (0)131 651 4151; Fax: +44 (0)131 650 9119;
28 20 Email: aziz.sheikh@ed.ac.uk

29 21

30 22
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **23 ABSTRACT**
4
5

6 **24 INTRODUCTION:** Anaphylaxis is an important, potentially life-threatening paediatric emergency. It is
7
8 responsible for considerable morbidity and, in some cases, death. Poor outcomes may be associated
9
10 with an inability to differentiate between milder and potentially more severe reactions and an
11
12 associated reluctance to administer self-injectable adrenaline. This study aims to assess the
13
14 effectiveness of 24-hour telephone access to specialist paediatric allergy expert advice in improving
15
16 the quality of life of children and their families with potentially life-threatening food allergy (i.e.
17
18 anaphylaxis) compared with usual clinical care.
19
20

21 **31 METHODS AND ANALYSIS:** Children aged less than 16 years with food allergy and who carry an
22
23 adrenaline auto-injector will be recruited from the Paediatric Allergy Clinic at Cork Hospital, Ireland
24
25 and baseline disease specific quality of life will be ascertained using the validated Food Allergy
26
27 Quality of Life Questionnaire (FAQLQ). Participants will be randomised for a period of six months to
28
29 the 24-hour telephone specialist support line or usual care. The primary outcome measure of
30
31 interest is a change in FAQLQ scores, which will be assessed at 1 and 6 months post-randomisation.
32
33 Analysis will be on an intention-to-treat basis using a 2x3 repeated measures within-between
34
35 ANOVA. Although lacking power, we will in addition assess the impact of the intervention on a range
36
37 of relevant process and clinical endpoints.
38
39

40 **40 ETHICS AND DISSEMINATION:** This trial protocol has been approved by the Clinical Research Ethics
41
42 Committee of the Cork Teaching Hospitals. The findings will be presented at international scientific
43
44 conferences and will be reported on in the peer-reviewed literature in early 2013.
45
46
47
48

49 **43 TRIAL REGISTRATION:** Current Controlled Trials: ISRCTN29793562
50
51
52
53
54
55
56
57
58
59
60

1
2
3 45 **INTRODUCTION**
4
5

6 46 Anaphylaxis is an important, potentially life-threatening paediatric emergency. Food is responsible
7
8 47 for the majority of anaphylaxis cases in the paediatric population.⁽¹⁾ Egg, milk, peanuts and tree nuts
9
10 48 are the most common food allergens in the preschool population; peanut and tree nuts are the most
11
12 49 common allergen triggers in older children. There is a wide spectrum of allergic reactions to these
13
14 50 allergens ranging from minor urticarial reactions to anaphylaxis, with the associated risk of fatality.
15

16
17 51 Anaphylaxis is managed via a two-pronged approach: firstly lifestyle modification to avoid the
18
19 52 allergen; and secondly the acute management of the anaphylactic event itself.^(2,3,4) Those children who
20
21 53 have had anaphylaxis, or who are judged to be at high risk of anaphylaxis, are prescribed adrenaline
22
23 54 (epinephrine) auto-injectors.⁽⁵⁾ These are to be carried on their person, or by their carers, at all times
24
25 55 in case of accidental exposure to the allergen(s) in question. This is important as, although
26
27 56 uncommon with an estimated incidence of one episode per 10 000 children per year,⁽⁵⁾ most
28
29 57 accidental exposures and subsequent reactions tend to occur in community settings⁽¹⁾ and because
30
31 58 of the typically rapid onset and progression of reactions, most young people and their families do
32
33 59 not have immediate access to medical support when this is most required.
34
35

36
37 60 Despite being prescribed an adrenaline auto-injector and being shown the correct method of
38
39 61 administration, many young people and/or parents still often report being unsure when to
40
41 62 administer this treatment.^(6,7) They often worry whether the reaction is severe enough to warrant an
42
43 63 injection of adrenaline or whether their child may come to harm if given unnecessary treatment.⁽⁸⁾
44
45 64 There is evidence that there is often a delay in administering the prescribed medication in an
46
47 65 emergency.⁽¹⁾ This delay in administering adrenaline may lead to increased morbidity and also
48
49 66 increases the risk of fatality.^(9,10) Allergy services therefore often encourage children and
50
51 67 families/carers to use their auto-injectors if there is any doubt regarding the severity of the allergic
52
53 68 reaction. Given the risk of further reactions and the above-described concerns about when to
54
55
56
57
58
59
60

1
2
3 69 administer emergency treatment, it is perhaps unsurprising that studies have found that food allergy
4
5 70 can have a detrimental impact both on the children themselves and also on family quality of life.^(11,12)
6
7 71 There is however as yet no clear evidence on how to improve clinical and/or psychological outcomes
8
9 72 in this population.

10
11
12 73 In the light of the above factors, we hypothesise that: firstly, uncertainty about the likely severity of
13
14 74 their child's reaction (ranging from no reaction to mild to life-threatening) on accidental re-exposure
15
16 75 to the allergenic food in question; and secondly, what a patient or carer must do if a reaction occurs,
17
18 76 both contribute significantly to parental/child anxiety. We further hypothesise that this uncertainty
19
20 77 could be ameliorated by real-time expert clinical guidance and support.

21
22
23
24 78 We propose therefore to test the effectiveness of giving parents and carers of children and
25
26 79 teenagers with known food allergy, who are medically considered to be at sufficient risk of
27
28 80 anaphylaxis that they have been prescribed and trained in the use of adrenaline auto-injectors, 24-
29
30 81 hour telephone access (intervention arm) or office hour access (routine care arm) to expert advice
31
32 82 from the clinical allergy service. We will advise parents/ carers/ teen patients randomised to the
33
34 83 intervention arm to ring this clinician-staffed advice line if they or their child has an allergic reaction
35
36 84 and they are unsure as to how to manage it. We postulate that the availability of this service will
37
38 85 improve disease-specific quality of life compared with families randomised to the routine care arm
39
40 86 who do not have this 24-hour access. We also suspect that the allergic reactions that parents or
41
42 87 families contact the allergy team about will be better managed as a result of the advice given. There
43
44 88 is currently no service such as this available in Ireland or indeed worldwide. This is, as far as we are
45
46 89 aware, the first ever randomised clinical trial of patient care in the field of anaphylaxis.⁽¹³⁾

47
48
49
50
51 90

52
53
54 91

55
56
57 92

1
2
3 93 **AIMS AND OBJECTIVES**
4
5

6 94 ***Aims***
7
8

9 95 We seek to assess the effectiveness of 24-hour telephone access to specialist paediatric allergy
10
11 96 expert advice in improving the quality of life of children and their families with potentially life-
12
13 97 threatening food allergy (i.e. anaphylaxis) compared with usual clinical care.
14

15
16 98 ***Main objective***
17
18

- 19 99 1. To compare the difference in food allergy related quality of life between the 24-hour
20
21 100 telephone access and usual care at one- and six-months post-randomisation.
22
23

24 101
25
26 102 ***Secondary objectives***
27

- 28 103 2. To compare the number and clinical severity of incidents of suspected/confirmed allergic
29
30 104 reaction in both groups
31
32 105 3. To compare clinical and health service use outcomes in both groups.
33
34

35 106
36
37
38 107 **METHODS AND ANALYSIS**
39
40

41 108 ***Design***
42
43

44 109 We will undertake a pragmatic two-arm parallel group randomised controlled trial.
45
46
47 110

48
49
50 111 ***Recruitment and consent***
51
52

53 112 All families with food allergic children seen in the paediatric allergy outpatient clinics at Cork
54
55 113 University Hospital will be informed about the study and invited to participate. A baseline validated
56
57
58
59
60

1
2
3 114 Food Allergy-specific Quality of Life questionnaire (FAQL) will be completed by interested family
4
5 115 members in relation to each child recruited.^(14,15,16) This FAQL questionnaire will be sent by post to each
6
7 116 family, with a stamp-addressed envelope.
8
9

10 117 Recruitment of families of children with food allergy who carry an adrenaline auto-injector will occur
11
12 118 in the paediatric allergy out-patient clinics of Cork University Hospital, which is the main centre for
13
14 119 specialist paediatric allergy service provision across Ireland. Notices with information about the
15
16 120 study will be placed around the out-patient waiting rooms. A phone number with a 24-hour
17
18 121 answering service will be advertised for families wishing to obtain further information about the
19
20 122 trial. Potentially suitable patients will also be identified from the weekly clinic preview team
21
22 123 meetings.
23
24

25
26 124 All potentially interested parents will be given further information about the study, and any
27
28 125 questions they may have will be answered. Children will, where appropriate on the basis of their age
29
30 126 and understanding, also be involved in this discussion. Written informed consent will be obtained
31
32 127 from all parents/guardians wishing to take part in the trial. Those over the age of eight years will also
33
34 128 be asked to sign an assent form in the presence of their parents.
35
36

37
38 129

39 40 41 130 ***Eligibility***

42
43
44 131 Families of children satisfying the inclusion and exclusion criteria detailed below will be eligible to
45
46 132 participate in the trial.
47

48 49 133 Inclusion criteria

- 50
51
52 134 1. <16 years of age
53
54 135 2. Food allergy
55
56 136 3. Previously prescribed an adrenaline auto-injector
57
58
59
60

- 1
2
3 137 4. Carers and, where appropriate, children trained by the clinical service how to use the
4
5 138 prescribed adrenaline auto-injector
6
7 139 5. First eligible food allergic child in a family with more than one eligible child.
8
9

10 140 Exclusion criteria
11
12

- 13 141 1. Awaiting food challenge and likely to undergo this challenge during the trial period
14
15 142 2. Experiencing another major life stressor during timeline of trial e.g. changing school
16
17 143 3. Second or subsequent eligible child in families with more than one already recruited child.
18
19

20 144
21

22
23 145 **Baseline assessment**
24
25

26 146 All study participants will, as noted above, fill out FAQL questionnaires prior to randomisation.
27
28 147 Parents will complete the FAQL Parent Form (FAQL-PF) as a proxy for their young children in those
29
30 148 less than 13 years. Children age 8-13 years will complete their own validated FAQL Child Form
31
32 149 (FAQL-CF) and teenagers will fill in the FAQL Teen form (FAQL-TF).
33
34
35

36 150
37
38

39 151 **Randomisation**
40
41

42 152 Randomisation will be undertaken only once all participants have been recruited, thereby
43
44 153 minimising the risk of any selection biases maintaining allocation concealment. When all baseline
45
46 154 questionnaires are collected the family will then be centrally randomised by the be independently
47
48 155 trial statistician, centrally randomised in a 1:1 ratio, into the intervention (I) or usual (U) care arms.
49
50 156 All recruited families will thus simultaneously be allocated to the (I) or (U) arms, this marking the
51
52 157 onset of the trial period.
53
54

55 158
56
57
58
59
60

1
2
3 159 ***Intervention and control***
4
5

6 160 The (I) group will be given a direct access mobile phone number to ring in the event of a suspected
7
8 161 serious allergic reaction. This will be given on a credit-card sized document for ease of access in the
9
10 162 event of an emergency. The manning of this emergency 24-hour helpline will be shared between
11
12 163 experienced members of the paediatric allergy team. In the event of a suspected serious allergic
13
14 164 reaction, the patient or his/her parent or carer will be able to ring the on-call trial clinician for
15
16 165 advice. Trial staff will have a standard incident report form (Appendix 1) to keep record of on-call
17
18 166 encounters. It is to be filled out as soon as is practical after the phone-call consultation. Their
19
20 167 advice will be tailored according to clinical need, but will include instructions that there is either: i.
21
22 168 no need for emergency treatment; ii. give antihistamines by mouth and observe; or iii. use the
23
24 169 adrenaline auto-injector and call an ambulance. The responding staff member will keep a record of
25
26 170 all such encounters and the advice given. Consistency of advice given is ensured by each staff
27
28 171 member giving out previously agreed, standardised instructions (Appendix 1) and by a
29
30 172 teleconference to be had between all personnel, following all incidents where advice is given on the
31
32 173 24-Hour Helpline, to discuss the incident and ensure that the standardised advice was given.
33
34
35

36
37 174 Those allocated to the U care (control) arm will receive standard care, with the option of contacting
38
39 175 one or more of the following: the Cork University Hospital Paediatric Allergy team during working
40
41 176 hours (Monday–Friday 8am-5pm), emergency/ambulance services, their own registered general
42
43 177 practitioner (GP), out-of-hours primary care providers or their nearest hospital Emergency
44
45 178 Departments .
46
47

48 179 The duration of trial period will be six months from the point of randomisation.
49
50

51 180
52
53

54 181 ***Outcome measures***
55
56
57
58
59
60

1
2
3 182 Primary
4
5

6 183 All study participants will complete the age-appropriate (discussed above) validated FAQL at one-
7
8 184 and six-months post randomisation; specifically, any change from baseline between intervention and
9
10 185 control groups at the one- and six-month assessment points.
11

12
13 186 The Food Allergy Quality of Life Questionnaire - Parent Form, Child Form, and Teen (FAQLQ-PF, -CF,
14
15 187 -TF) are age appropriate parent-administered, child self administered, and teen self administered
16
17 188 questionnaires that measure the impact of food allergy on HRQL of children age 0-18 years. They
18
19 189 were developed and validated under the auspices of EuroPrevall, a European Commission funded
20
21 190 project with over 60 partners (www.europrevall.org). We have previously demonstrated good cross-
22
23 191 sectional and longitudinal reliability and validity in European and US samples. The questionnaire
24
25 192 items are scored on a 7-point likert scale ranging from 0 (no impact on HRQL) to 6 (extreme impact
26
27 193 on HRQL). The measures have three subscales assessing general emotional impact; food anxiety;
28
29 194 social and dietary limitations. The total score is calculated as the mean of these three subscales.⁽¹⁴⁻¹⁷⁾
30
31
32

33 195 Secondary
34
35

36 196 Participants in both groups will also be asked to record any possible allergic reactions that may have
37
38 197 occurred, which were self-managed and/or required medical advice or attention other than
39
40 198 provided through the trial helpline. They will be provided with a standardised form to record this
41
42 199 information on (See Appendix 2). We will record the clinical details of every reported event to
43
44 200 include: incidence, severity, administration of adrenaline, hospital attendance and death
45
46
47

48 201
49

50
51 202 ***Statistical considerations***
52

53
54 203 Analysis
55
56
57
58
59
60

1
2
3 204 We will assess the statistical significance and relative magnitude of changes over three time-points
4
5 205 i.e. at baseline (T0), one month (T1) and six-months (T2) post-randomisation, on the FAQL scores for
6
7 206 both the (I) and (U) care groups using a repeated measures 2x3 multivariate design.⁽¹⁸⁾ That is, the
8
9 207 same case in either experimental or control group (group factor), will complete the questionnaires
10
11 208 at three time-points (time factor). The effect of the factors 'time' and 'group' on the total score, and
12
13 209 the interaction of these two factors, will be analysed using a two-way within-between groups
14
15 210 ANOVA. The interaction will address the question; 'Are the time profiles in terms
16
17 211 of FAQL total scores of the two groups (experimental/control) significantly different'? If
18
19 212 improvement over time is determined, a paired sample t-test will be used to ascertain at which
20
21 213 time-point(s) the difference can be detected. Secondary outcomes will be included in univariate and
22
23 214 multivariate models as independent and dependent variables and controls.
24
25
26
27

28 215 Independent t-tests will be used to determine if there are differences in magnitude of improvement
29
30 216 in FAQL scores for (I) vs. (U) groups. The Bonferroni correction method will be used to adjust for
31
32 217 multiple comparisons.
33
34

35 218 We will calculate the responsiveness index (mean change score/SD of change score), using Cohen's
36
37 219 change index benchmarks; 0.2–0.4 (small); 0.5–0.7 (moderate); and 0.81 (large).
38
39

40 220 We will assess the reliability of the change score by computing the intra-class coefficients of change
41
42 221 in the FAQLQ. The minimal important difference (MID) will also be calculated. Because the validity
43
44 222 of a retrospective assessment of change has been questioned, we will determine the MID by
45
46 223 computing the standard error of measurement (SEM ($sp(1-r)$)), using baseline FAQLQ scores as an
47
48 224 'anchor'.
49
50

51
52
53 225
54
55
56
57
58
59
60

226 Missing data will be dealt with by the Multiple Imputation (MI) method, which is suitable for ANOVA
 227 and uses an imputation method with error built in.⁽¹⁹⁾

228

229 Analysis will be on an intention-to-treat basis by the trial statistician who will be blinded to
 230 allocation. There are no interim analyses planned.

231 Power

232 We will utilise a within/between repeated measures analysis of variance. An a priori total sample
 233 size required x power (1- β err prob), for a repeated measures within-between ANOVA analysis is 16
 234 in each group (intervention/control) to yield a statistically significant result at >90% power with a
 235 0.5 effect level.⁽²⁰⁾

236 'Within' refers to expected differences between three time periods (T0, T1 and T2) and 'between'
 237 refers to expected differences between the intervention and control groups.

238

239 **F tests** - ANOVA: Repeated measures, within-between interaction

240 **Analysis:** A priori: Compute required sample size

241 **Input:** Effect size f = 0.5

242 α err prob = 0.05

243 Power (1- β err prob) = 0.95

244 Number of groups = 2

245 Repetitions = 3

246 Corr among rep measures = 0.4

247 Nonsphericity correction ϵ = 1

248 **Output:** Noncentrality parameter λ = 20.000000

249 Critical F = 3.340386

| | | | |
|-----|-------------------|---|-----------|
| 250 | Numerator df | = | 2.000000 |
| 251 | Denominator df | = | 28.000000 |
| 252 | Group sample size | = | 16 |
| 253 | Actual power | = | 0.973792 |

254 **ETHICS AND DISSEMINATION**

255 Ethical approval has been obtained by the Clinical Research Ethics Committee of the Cork Teaching
256 Hospitals (30.05.2011). All patients are aware that their participation is voluntary and they may
257 withdraw from study at any time.

258

259 The PI for the trial is Jonathan Hourihane and he will lead the Trial Management Group and he is
260 responsible for the overall governance and running of this trial. Other members of the Trial
261 Management Group are: Maeve Kelleher, John Fitzsimons, Audrey DunnGalvin, Claire Cullinane and
262 Aziz Sheikh, and they will support the PI in delivering this trial. Audrey DunnGalvin is the trial
263 statistician.

264 We plan to report our findings at major national and international scientific conferences. We also
265 plan to publish our findings in the peer-reviewed literature. We anticipate being in a position to
266 report on findings in early 2013.

267

268 **ACKNOWLEDGEMENTS:** We are very grateful to the children and their families who have agreed to participate in this trial.

269 **CONFLICT OF INTERESTS:** None known.

270 **AUTHORS' CONTRIBUTIONS:** JOH and AS conceived the idea for this trial, and this was then further developed in
271 association with MH and ADG. MH led the drafting of this manuscript, which was critically commented on by all co-authors.

1
2
3 272 **FUNDING STATEMENT:** 'This research received no specific grant from any funding agency in the public, commercial or not-
4
5 273 for-profit sectors.
6

7 274

8
9 275

10
11 276

12
13 277

14
15 278 **REFERENCES**

16
17 279 1. De Silva SL, Mehr S, Tey D, et al. Paediatric anaphylaxis: a 5 year retrospective review.
18 280 *Allergy* 2008; 63: 1071–107.

19
20
21 281 2. Walker S, Sheikh A. Managing anaphylaxis: effective emergency and long-term care are
22 282 necessary. *Clin Exp Allergy* 2003; 33: 1015-18.

23
24 283 3. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines
25 284 for healthcare providers. Working Group of the Resuscitation Council (UK). *Resuscitation*
26 285 2008; 77: 157-69

27
28
29 286 4. Simons FE, Arduoso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines:
30 287 Summary. *J Allergy Clin Immunol* 2011; 127: 587-93.e1-22.

31
32 288 5. Muraro A, Roberts G, Clark A et al The management of anaphylaxis in childhood: position
33 289 paper of the EAACI. *Allergy* 2007; 62: 857–71.

34
35 290 6. Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an
36 291 epinephrine autoinjector device (EpiPen). *J Allergy Clin Immunol* 2000; 106: 171-76.

37
38 292 7. Arkwright P, Farragher AJ. Factors determining the ability of parents to effectively
39 293 administer intramuscular adrenaline to food allergic children. *Pediatr Allergy Immunol* 2006;
40 294 17: 227–29.

41
42
43 295 8. Kim S, Sincacore J, Pongracic J. Parental use of EpiPen for children with food allergies. *J*
44 296 *Allergy Clin Immunol* 2005; 116: 164-68.

45
46 297

47
48 298 9. Sampson HA, Mendelson L, Rosen JP(1992) Fatal and near-fatal anaphylactic reactions to
49 299 food in children and adolescents. *N Engl J Med.* 327:380–384.

50
51 300 10. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. *Clin*
52 301 *Exp Allergy.* 2000 30(8):1144–1150.

53
54
55 302

- 1
2
3 303 11. Sicherer S, Noone S, Munoz-Furlong. The impact of childhood food allergy on quality of life.
4 304 *Ann Asthma, Allergy Immunol* 2001; 87: 461-464.
5
6 305 12. Avery N, King RM, Knight S, et al. Assessment of quality of life in children with peanut
7 306 allergy. *Pediatr Allergy Immunol* 2003; 14: 378–82.
8
9 307 13. Simons FE, Sheikh A. Evidence-based management of anaphylaxis. *Allergy* 2007; 62: 827-29.
10
11 308 14. DunnGalvin A, de BlokFlokstra BM, Burks AW, et al. Food allergy QoL questionnaire for
12 309 children aged 0-12 years: content, construct, and cross-cultural validity. *Clin Exp Allergy*
13 310 2008; 38: 977-86.
14
15 311 15. Flokstra-de Blok BM, DunnGalvin A, Vlieg-Boerstra BJ, et al. Development and validation of
16 312 the self-administered Food Allergy Quality of Life Questionnaire for Adolescents. *J Allergy*
17 313 *Clin Immunol* 2008; 122: 139-144.e2
18
19 314 16. de BlokFlokstra, DunnGalvin A, Vlieg-Boerstra BJ, et al. Development and validation of a self-
20 315 administered Food Allergy Quality of Life Questionnaire for children. *Clin Exp Allergy* 2009;
21 316 39: 127–37.
22
23 317 17. Hourihane J.O’B., Chiang, WC, et al. Psychometric validation of the FAQLQ-PF in a US sample
24 318 of children with food allergy. *J Aller Clin Immunol* 2008; 121-2:1: S106-S107.
25
26 319 18. Hinkelmann, Klaus & Kempthorne, Oscar. *Design and analysis of experiments*. 2008; I and II
27 320 (Second ed.). Wiley
28
29 321 19. Graham JW. Missing data analysis: making it work in the real world. *Ann Rev Psychol* 2009;
30 322 60: 549-76.
31
32 323 20. Cohen J. A power primer. *Psychol Bull* 1992; 112: 155–59.
33
34 324
35 325
36 326
37 327
38 328
39 329
40 330
41 331
42 332
43 333
44 334
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 335
4
5 336
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

337 **Appendix 1: Incident Report Form**

338 Patient Name _____

339 Staff member Name _____

340 Caller Mother/father/ patient/ other _____

341 (Please specify)

342 Time of call (24h) __:__:__ h

343

344 Patient location _____

345 Food suspected _____

346 How much eaten? _____

347 Time since ingestion _____

348 Asthma y/n _____

349

350

351 **Current condition**

Advice to be given

352 Rash only Give antihistamine, Do not Use Anapen yet

353 Rash and swelling Give antihistamine, Do Not Use Anapen yet

354 Cough/hoarseness Use Anapen, call ambulance, go to hospital

355 Wheeze Use Anapen, call ambulance, go to hospital

356 Dizzy/collapse Use Anapen, call ambulance, go to hospital

357

358

359 Outcome (to be completed by study team in Cork, ASAP next working day)

360

361

362

363

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

364

365

366 **Appendix 2.**



UCC
Coláiste na hOllscoile Corcaigh, Éire
University College Cork, Ireland

367

368

Anaphylaxis 24-hour Helpline Study

369

Record of any Food Allergy Reactions

370


Study Number __

371

| Food | Symptoms | How long after eating? | What Treatment Given? | Did you attend doctor? | Outcome |
|------|----------|------------------------|-----------------------|------------------------|---------|
| | | | | | |
| | | | | | |
| | | | | | |

372

Figure 1: A – priori total sample size required x power (1-β err prob), for a repeated measures within-between ANOVA analysis



With an anticipated drop-out rate of 20%, we therefore plan to recruit a total of 40 families.